KRAS and ovarian carcinoma: The genomic amplification of KRAS, in particular, is associated with metastatic disease and poor prognosis in hormone-related cancers such as ovarian cancer [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21].